These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 34740610)

  • 1. A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo.
    Baek DS; Kim YJ; Vergara S; Conard A; Adams C; Calero G; Ishima R; Mellors JW; Dimitrov DS
    Cancer Lett; 2022 Jan; 525():97-107. PubMed ID: 34740610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
    DeLucia DC; Cardillo TM; Ang L; Labrecque MP; Zhang A; Hopkins JE; De Sarkar N; Coleman I; da Costa RMG; Corey E; True LD; Haffner MC; Schweizer MT; Morrissey C; Nelson PS; Lee JK
    Clin Cancer Res; 2021 Feb; 27(3):759-774. PubMed ID: 33199493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.
    Lee JK; Bangayan NJ; Chai T; Smith BA; Pariva TE; Yun S; Vashisht A; Zhang Q; Park JW; Corey E; Huang J; Graeber TG; Wohlschlegel J; Witte ON
    Proc Natl Acad Sci U S A; 2018 May; 115(19):E4473-E4482. PubMed ID: 29686080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
    Imberti C; De Gregorio R; Korsen JA; Hoang TT; Khitrov S; Kalidindi T; Nandakumar S; Park J; Zaidi S; Pillarsetty NVK; Lewis JS
    J Nucl Med; 2024 Jul; 65(7):1043-1050. PubMed ID: 38782457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates.
    Kim YJ; Li W; Zhelev DV; Mellors JW; Dimitrov DS; Baek DS
    Front Oncol; 2023; 13():1124039. PubMed ID: 36923424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
    Thistlethwaite FC; Gilham DE; Guest RD; Rothwell DG; Pillai M; Burt DJ; Byatte AJ; Kirillova N; Valle JW; Sharma SK; Chester KA; Westwood NB; Halford SER; Nabarro S; Wan S; Austin E; Hawkins RE
    Cancer Immunol Immunother; 2017 Nov; 66(11):1425-1436. PubMed ID: 28660319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors.
    Decary S; Berne PF; Nicolazzi C; Lefebvre AM; Dabdoubi T; Cameron B; Rival P; Devaud C; Prades C; Bouchard H; Cassé A; Henry C; Amara C; Brillac C; Ferrari P; Maçon L; Lacoste E; Combeau C; Beys E; Naimi S; García-Echeverría C; Mayaux JF; Blanc V
    Clin Cancer Res; 2020 Dec; 26(24):6589-6599. PubMed ID: 33046521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Abdoli S; Modarressi MH; Abolhassani M
    Iran Biomed J; 2020 Mar; 24(2):81-8. PubMed ID: 31677604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.
    Su Y; Liu Y; Behrens CR; Bidlingmaier S; Lee NK; Aggarwal R; Sherbenou DW; Burlingame AL; Hann BC; Simko JP; Premasekharan G; Paris PL; Shuman MA; Seo Y; Small EJ; Liu B
    JCI Insight; 2018 Sep; 3(17):. PubMed ID: 30185663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
    J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5) and dipeptidyl peptidase-4 (DPP4) with detection of Middle East respiratory syndrome-coronavirus in peripheral blood.
    Alhetheel A; Albarrag A; Shakoor Z; Somily A; Barry M; Altalhi H; Bakhrebah M; Nassar M; Alfageeh M; Assiri A; Alfaraj S; Memish ZA
    J Infect Public Health; 2022 Nov; 15(11):1315-1320. PubMed ID: 36279687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway.
    Fantini M; David JM; Annunziata CM; Morelli MP; Arlen PM; Tsang KY
    Cancer Biother Radiopharm; 2020 Apr; 35(3):190-198. PubMed ID: 31928422
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
    Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
    Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
    [No Abstract]   [Full Text] [Related]  

  • 14. Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma.
    Zhang C; Wang L; Zhang Q; Shen J; Huang X; Wang M; Huang Y; Chen J; Xu Y; Zhao W; Qi Y; Li Y; Ou Y; Yang Z; Qian C
    Front Immunol; 2023; 14():1182409. PubMed ID: 37304295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer.
    Van Emmenis L; Ku SY; Gayvert K; Branch JR; Brady NJ; Basu S; Russell M; Cyrta J; Vosoughi A; Sailer V; Alnajar H; Dardenne E; Koumis E; Puca L; Robinson BD; Feldkamp MD; Winkis A; Majewski N; Rupnow B; Gottardis MM; Elemento O; Rubin MA; Beltran H; Rickman DS
    Cancer Res Commun; 2023 Aug; 3(8):1447-1459. PubMed ID: 37546702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel exosome based therapeutic intervention against neuroendocrine prostate cancer.
    Saini S; Sreekumar A; Nathani S; Asante DM; Simmons MN
    Sci Rep; 2024 Feb; 14(1):2816. PubMed ID: 38307935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine.
    Cha SE; Kujawski M; J Yazaki P; Brown C; Shively JE
    Oncoimmunology; 2021 Mar; 10(1):1899469. PubMed ID: 33796409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
    Weimin S; Abula A; Qianghong D; Wenguang W
    Cancer Biol Ther; 2020 Jun; 21(6):570-580. PubMed ID: 32208880
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
    Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
    BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial.
    Dorff TB; Blanchard MS; Adkins LN; Luebbert L; Leggett N; Shishido SN; Macias A; Del Real MM; Dhapola G; Egelston C; Murad JP; Rosa R; Paul J; Chaudhry A; Martirosyan H; Gerdts E; Wagner JR; Stiller T; Tilakawardane D; Pal S; Martinez C; Reiter RE; Budde LE; D'Apuzzo M; Kuhn P; Pachter L; Forman SJ; Priceman SJ
    Nat Med; 2024 Jun; 30(6):1636-1644. PubMed ID: 38867077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.